In this context, data collected so far indubitably document that high LGALS3BP expression levels in tissues and serum are associated with unfavorable clinical outcomes in a wide variety of malignancies, including breast [6, 11–25] and lung [8, 26–29] cancer, melanoma [10, 30–36], ovarian [37–42], hepatocellular [36, 43–46], pancreatic [47–50], prostatic [51, 52] and oral squamous cell [53–59] carcinomas, neuroblastoma [60–63], glioblastoma [64, 65], gastric cancer [66] and lymphoma [67]. Here, LGALS3BP is linked to neuroblastoma.